Global Blood Therapeutics
181 Oyster Point Blvd
South San Francisco
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
212 articles with Global Blood Therapeutics
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK
Global Blood Therapeutics, Inc. announced that the Medicines and Healthcare Products Regulatory Agency in the United Kingdom has granted a Promising Innovative Medicine designation for voxelotor for the potential treatment of hemolytic anemia in adults and adolescent patients 12 years of age and older with sickle cell disease.
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
Global Blood Therapeutics, Inc. announced new data from the Phase 2a HOPE-KIDS 1 Study that showed children with sickle cell disease ages 4 to 11 years treated with Oxbryta® tablets experienced significant improvements in hemoglobin levels.
Global Blood Therapeutics, Inc. announced that on June 1, 2021, the compensation committee of GBT’s board of directors granted 11 new employees options to purchase an aggregate of 35,500 shares of the company’s common stock with a per share exercise price of $37.20 and restricted stock units for an aggregate of 45,410 shares of the company’s common stock.
Global Blood Therapeutics, Inc. announced that it will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 8, 2021, at 2:10 p.m. Eastern Time.
GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress
New Oxbryta® (voxelotor) Data from Phase 2a HOPE-KIDS 1 Study Demonstrate Improvement in Hemoglobin and Hemolysis in Children Ages 4 to 11 Years with Sickle Cell Disease
5/11/2021Despite the COVID-19 pandemic taking a hit on other industries, the biotech industry continues to grow and so do salaries. Biotech companies keep adding jobs and the market is hot! Check out these hot companies who are looking for candidates like you right now!
Global Blood Therapeutics, Inc. announced that it will participate in virtual fireside chats at the following investor conferences
Achieved Oxbryta® (voxelotor) net revenues of $39.0 million; on track with plans to potentially expand access to Oxbryta in the U.S. and Europe
GBT and Sickle Cell Disease Association of America Kick Off “Lift Every Voice to Shine the Light on Sickle Cell” Spoken Word Contest in Honor of World Sickle Cell Day 2021
In recognition of World Sickle Cell Day, which falls on June 19, 2021, Global Blood Therapeutics, Inc. and the Sickle Cell Disease Association of America, Inc. launched “Lift Every Voice to Shine the Light on Sickle Cell” – a contest that will feature original spoken word pieces to raise awareness of sickle cell disease.
Global Blood Therapeutics, Inc. announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021, after U.S. financial markets close.
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients
Global Blood Therapeutics, Inc. announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study of Oxbryta® tablets in patients with sickle cell disease.
Global Blood Therapeutics, Inc. announced that on April 1, 2021, the compensation committee of GBT’s board of directors granted 12 new employees restricted stock units for an aggregate of 47,750 shares of the company’s common stock.
The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were tr...
3/19/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Alexis A. Thompson, M.D., M.P.H., a world-renowned hematologist and sickle cell disease (SCD) expert, to the company’s board of directors.
GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.
Global Blood Therapeutics, Inc. announced it has entered into an agreement with Sanofi S.A. to exclusively in-license worldwide rights to two early-stage research programs in sickle cell disease : one that pursues a novel anti-sickling mechanism and another that leverages a new approach to reduce inflammation and oxidative stress.
Global Blood Therapeutics, Inc. announced that on March 1, 2021, the compensation committee of GBT’s board of directors granted 14 new employees options to purchase an aggregate of 11,525 shares of the company’s common stock with a per share exercise price of $44.48 and restricted stock units for an aggregate of 43,800 shares of the company’s common stock.
GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease CommunityGrant proposals from community-based organizations and institutions accepted through April 23, 2021
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it is accepting proposals for the third annual Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program, which provides funding to accelerate the development of sustainable access-to-care programs for people living with sickle cell disease (SCD).
Global Blood Therapeutics, Inc. will participate at the H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021. A presentation by Ted W. Love, M.D., president and CEO of GBT, will be available at 7:00 a.m. ET.
Further established leadership in sickle cell disease (SCD) with data presentations on pipeline programs inclacumab and GBT021601 (GBT601)